In its upcoming report, Thermo Fisher Scientific (TMO) is predicted by Wall Street analysts to post quarterly earnings of $5.50 per share, reflecting an increase of 4.2% compared to the same period last year. Revenues are forecasted to be $10.9 billion, representing a year-over-year increase of 2.8%.The consensus EPS estimate for the quarter has undergone a downward revision of 0.5% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed ...

​Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the Best Forever Stocks to Invest In Now. On October 9, J.P. Morgan analyst Casey Woodring raised the firm’s price target on Thermo Fisher Scientific Inc. (NYSE:TMO) from $600 to $650, while keeping an Overweight rating on the stock. ​The rating comes ahead of the company’s fiscal third-quarter results, which are expected on October 22, 2025. The analyst noted that they see the life sciences tool companies taking a more conservative stance in their 2026 ...

Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. Valued at $9.3 billion by market cap, the company specializes in proteins, cytokines, growth factors, immunoassays and small molecules. The leading life sciences reagents and instruments company is expected to announce its fiscal first-quarter earnings for 2026 in the near term. Ahead of the even ...

With a market cap of $22.9 billion, Labcorp Holdings Inc. (LH) is a leading global life sciences company that provides comprehensive diagnostic, drug development, and laboratory services. Headquartered in Burlington, North Carolina, Labcorp operates a network of laboratories and testing facilities, offering services ranging from routine clinical testing to advanced genomics and clinical trial solutions. LH is scheduled to report its Q3 earnings on Tuesday, Oct. 28, before the market opens. Ahead of the ev ...

Key Takeaways Thermo Fisher partners with AstraZeneca at BioVentureHub to drive collaborative R&D in life sciences.Thermo Fisher's new Gothenburg lab at BioVentureHub will support global pharma and biotech R&D by 2026.The AZN partnership advances drug and analytical development, reinforcing Thermo Fisher's mission globally.Thermo Fisher Scientific’s (TMO) clinical research business, PPD, announced a new research and development (R&D) partnership with AstraZeneca’s (AZN) BioVentureHub in Gothenburg, Sweden. ...

According to their latest 13F filings, institutional investors made a series of notable moves in Thermo Fisher Scientific (TMO), highlighting conviction in the company’s role as a global leader in life sciences tools, diagnostics, and biopharma services. The stock continues to attract attention from some of the world’s most prominent asset managers, with multiple funds significantly increasing their positions.Let’s examine some of the most notable changes:Grantham, Mayo, Van Otterloo & Co. LLC (Jeremy Grant ...

Core Viewpoint - Thermo Fisher Scientific Inc. has announced a $2.5 billion offering of senior notes, indicating a strategic move to raise capital for future investments and operations [1] Group 1: Offering Details - The offering includes $500 million of 4.200% senior notes due in 2031, priced at 99.874% of their principal amount [1] - Additionally, the offering consists of $750 million of 4.473% senior notes due in 2032, priced at 100.00% of their principal amount [1]

Thermo Fisher Scientific Inc (NYSE:TMO) experienced a significant Power Inflow alert, a key bullish indicator that is closely tracked by traders who value order flow analytics, specifically institutional and retail order flow data.At 10:36 AM EST on September 30, TMO triggered a Power Inflow signal at a price of $464.71. Prior to the alert, TMO had been stagnant during the first hour of trading, with the stock price not moving far off the opening price. At the time of the Power Inflow signal, both the insti ...

Group 1 - Mairs & Power Balanced Fund reported a return of 2.66% in the first half of 2025, underperforming benchmark indexes which rose 5.43% and 5.67% respectively [1] - The fund's performance was impacted by external factors such as tariff uncertainty, conflicts in the Middle East, and rising national debt [1] - The fund experienced a recovery, rising 25% from its low at the beginning of the quarter [1] Group 2 - Bio-Techne Corporation (NASDAQ:TECH) has a market capitalization of $8.239 billion and focuses on life science reagents, instruments, and services [2] - The stock of Bio-Techne Corporation saw a one-month return of -5.87% and a 52-week decline of 29.39%, closing at $52.92 per share on September 23, 2025 [2] - The company underperformed due to uncertainty in the funding environment, influenced by federal funding cuts and a weak venture capital landscape [3] Group 3 - Bio-Techne Corporation generated $317 million in revenues in the fiscal fourth quarter of 2025, reflecting a 3% year-over-year increase on an organic basis and a 4% increase on a reported basis [4] - The company is not among the 30 most popular stocks among hedge funds, with 37 hedge fund portfolios holding its stock at the end of the second quarter, up from 34 in the previous quarter [4] - Despite acknowledging Bio-Techne's potential, the company believes certain AI stocks present greater upside potential and lower downside risk [4]

Core Viewpoint - Tempus AI, Inc. has received 510(k) clearance from the FDA for its RNA-based Tempus xR IVD device, which will enhance precision medicine and patient care through advanced RNA sequencing technology [1] Company Summary - Tempus AI, Inc. is a technology company focused on integrating AI to improve precision medicine and patient care [1] - The Tempus xR IVD device is positioned as a life sciences tool aimed at supporting drug development programs [1] Industry Summary - RNA sequencing technology is highlighted for its ability to capture extensive biological information, providing deeper insights into disease mechanisms [1]